Necrotizing Enterocolitis: What's New and What's Next?

Necrotizing enterocolitis (NEC) is a significant cause of morbidity and mortality for preterm infants in the neonatal intensive care unit. From the first surgical approaches for NEC in the 1970s and the development of Bell's staging criteria, there has been a continuous medical and scientific journey towards understanding the pathophysiology, clinical progression, and treatment possibilities for this devastating disease. Basic science research has played a crucial role in understanding the pathogenesis of NEC. In vivo NEC models, which include rodents (mice, rats) and pigs, and in vitro NEC models, which utilize intestinal cell lines and organoids, have identified critical disease biomarkers, pathways in NEC pathogenesis, and novel therapeutic targets. These potential therapies have been brought into clinical trials to improve treatment options for infants with NEC. This review will provide a comprehensive assessment of research conducted over the last decade, leading to a deeper understanding of the disease's development and progression through the use of innovative models, the identification of novel biomarkers, the development of new therapeutic approaches, and, finally, an overview of the latest clinical trials. We will conclude with a discussion of ongoing challenges and future research directions, highlighting the optimism and hope that these advancements bring to the field of neonatology and pediatric surgery. This review will serve as a reference and guide for future NEC research, with the ultimate goal of enhancing clinical outcomes and improving the quality of life for patients with NEC and their families.